TRX Biosciences Limited is pioneering advancements in drug biodistribution, focusing on targeted oral drug delivery systems that enhance the efficacy of treatments for various diseases, including cancer, central nervous system disorders, respiratory diseases, and immune system conditions. Their innovative technology addresses historical challenges in drug absorption by utilizing unexploited uptake channels within human biology. This approach allows for high drug loads to be incorporated into chylomicrons, facilitating systemic distribution while minimizing the effects of first-pass metabolism. By priming key immune cells and enhancing drug uptake in specific organs, TRX aims to revolutionize the design and delivery of small molecule-based oral therapies.

The company's strategy emphasizes the transport and targeting of therapeutics directly to disease sites, significantly improving drug absorption and distribution. TRX's technology not only enhances the systemic absorption of drugs but also opens new avenues for generating regulatory immune cells with a broader systemic reach. With a robust intellectual property portfolio and a proven track record in overcoming complex pharmacokinetic and pharmacodynamic challenges, TRX Biosciences is positioned to transform the landscape of oral drug delivery, making previously unexploitable pharmacology clinically significant.

United Kingdom

TRX's technology enables targeted oral drug delivery to specific organs, cells and tissues in cancer, CNS and respiratory diseases and diseases of the immune system using a clinically and commercially proven approach.

TRX Biosciences Limited

Company Details